Abstract
The application claims new therapeutic approaches for treatment of existing atherosclerotic lesions. The basic claim of the patent is the use of passive or active immunization with oxidized ApoB-100 peptides in order to prevent and reverse atherosclerosis-related cardiovascular disease. The claimed approaches are valid and the published data by this group and others suggest that they may potentially result in the development of novel therapies complementary to other methods presently used for treatment of atherosclerosis.